

Prostate Cancer Therapy Breaks Deemed Risky

BY JANE SALODOF MACNEIL
Senior Editor

LOS ANGELES — For men with low-risk prostate cancer, skipping more than two sessions of radiotherapy beyond their scheduled weekends off can have long-term consequences, investigators found when they reviewed nearly 1,800 patients treated from 1989 to 2004 at a single cancer center.

Biochemical control at 5 and 10 years was significantly worse for men who skipped more than 2 days even though they ultimately completed their treatments, Dr. David J. D'Ambrosio reported at the annual meeting of the American Society for Therapeutic Radiation and Oncology.

The impact of treatment interruptions was significant for the population as a whole, but the disparity was driven by a highly significant difference within the low-risk group. Interruptions had little to no impact in men with medium- or high-risk disease.

At 5 years the freedom-from-biochemical-failure (FFBF) rate was 90% in patients who skipped the equivalent of more than 2 days for low-risk prostate cancer versus 95% in those who took shorter breaks or no breaks. At 10 years, the FFBF rates were 57% and 82%, respectively.

"Our hypothesis for why this was seen in the low-risk group is that the low-risk patients are the ones most likely to have cancer just confined to the prostate. So ... they are the ones who have the most to gain and lose from the local treatment," Dr. D'Ambrosio, a radiation oncology resident at Fox Chase Cancer Center in Philadelphia, said during an interview.

Findings of previous studies have conflicted on the question of whether small interruptions in prostate cancer treatment can be harmful, Dr. D'Ambrosio said.

The new study identified 1,796 men who received 3-D conformal radiation therapy (76%) or intensity-modulated radiation therapy (24%) between April 1989 and November 2004 at Fox Chase. None had androgen deprivation therapy.

The median dose was 76 Gy, median patient age was 69 years, and median follow-up was 62 months. On the basis of a Gleason score, pretreatment prostate-specific antigen (PSA) levels, and tumor stage, the patients were stratified into three groups: high risk (209 patients, 12%), medium risk (798 patients, 44%), and low risk (789 patients, 44%). The investigators created a nontreatment days ratio (NTDR). They calculated each patient's NTDR by dividing the total elapsed days during treatment into the number of nontreatment days during a course of treatment.

The investigators determined that patients with a ratio of 33% or higher were less likely to maintain long-term biochemical control. "This is the first time [the impact of skipped treatment days] has been shown, and it needs to be repeated before it is taken as dogma," Dr. D'Ambrosio said. ■

Cialis Gets Approved for Once-Daily Use

BY BROOKE McMANUS
"The Pink Sheet"

The erectile dysfunction drug Cialis (tadalafil) has been approved by the Food and Drug Administration for once-daily use in 2.5-mg and 5-mg doses, the drug's manufacturer announced.

"This low-dose daily treatment option of Cialis may be most appropriate for men with ED who anticipate more frequent sexual activity," according to a

statement issued by Eli Lilly & Co. "For other men, Cialis taken as needed—the previously approved dosing regimen—may be most appropriate."

Cialis was approved in 2003 in 5-mg, 10-mg, and 20-mg doses as the first and only phosphodiesterase type 5 inhibitor to provide sustained efficacy for up to 36 hours.

The approval of Cialis once daily is based on results from three phase III randomized, double-blind, placebo-controlled studies, which demonstrated that

men with erectile dysfunction who took tadalafil 2.5 mg or 5 mg once daily without regard to their timing of sexual activity experienced improved erectile function, compared with placebo, the statement said.

The most commonly reported adverse events were headache, indigestion, back pain, muscle aches, nasal congestion, flushing, and pain in a limb. These side effects were transient.

FAMILY PRACTICE NEWS and "The Pink Sheet" are published by Elsevier. ■

PROVIGIL®
(MODAFINIL)®
Tablets

Cephalon

© 2007 Cephalon, Inc. All rights reserved.
PRO1068 Oct 2007 Printed in USA.

PROVIGIL cuts through the fog of excessive sleepiness (ES) associated with obstructive sleep apnea (OSA), when used as an adjunct treatment



Help your patients with OSA cut through the fog of ES with PROVIGIL

- PROVIGIL is a nonamphetamine wake-promoting agent
- PROVIGIL helps patients with ES associated with OSA stay awake
- PROVIGIL significantly improves clinical condition
- Sleep as measured by polysomnography was not affected by the use of PROVIGIL
- PROVIGIL is generally well tolerated
 - The most frequently reported adverse events (≥5%) were headache, nausea, nervousness, rhinitis, diarrhea, back pain, anxiety, insomnia, dizziness, and dyspepsia

PROVIGIL is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder.

In OSAHS, PROVIGIL is indicated as an adjunct to standard treatment(s) for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating PROVIGIL. If PROVIGIL is used adjunctively with CPAP, the encouragement of and periodic assessment of CPAP compliance is necessary.

Important Information for Physicians

Rare cases of serious or life-threatening rash, including SJS, Toxic Epidermal Necrolysis (TEN) and Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) have been reported, postmarketing, in adults and children taking PROVIGIL. PROVIGIL should ordinarily be discontinued at the first sign of rash unless the rash is clearly not drug-related. PROVIGIL is not approved for use in pediatric patients for any indication.

Angioedema has been reported in postmarketing experience with PROVIGIL. Patients should be advised to discontinue therapy and immediately report to their physician any signs or symptoms suggesting angioedema or anaphylaxis.

Multi-organ hypersensitivity reactions, including at least 1 fatality postmarketing, have occurred in close temporal association to the initiation of PROVIGIL. If a multi-organ hypersensitivity reaction is suspected, PROVIGIL should be discontinued.

Patients should be advised that their level of wakefulness may not return to normal. Patients should be frequently reassessed for their degree of sleepiness and, if appropriate, advised to avoid driving or any other potentially dangerous activity.

Psychiatric adverse experiences have been reported in patients treated with PROVIGIL. Caution should be exercised when PROVIGIL is given to patients with a history of psychosis, depression, or mania. Consider discontinuing PROVIGIL if psychiatric symptoms develop.

Patients with a recent history of myocardial infarction or unstable angina should be treated with caution. PROVIGIL tablets should not be used in patients with a history of left ventricular hypertrophy or in patients with mitral valve prolapse who have experienced the mitral valve prolapse syndrome when previously receiving CNS stimulants. Increased monitoring of blood pressure may be appropriate in patients on PROVIGIL.

In clinical trials, most adverse experiences were mild to moderate. The most frequently reported adverse events (≥5%) were headache, nausea, nervousness, rhinitis, diarrhea, back pain, anxiety, insomnia, dizziness, and dyspepsia.

PROVIGIL is a Schedule IV drug. PROVIGIL produces psychoactive and euphoric effects, alterations in mood, perception, thinking and feelings typical of other CNS stimulants. Physicians should follow patients closely, especially those with a history of drug and/or stimulant abuse.

Please see brief summary of full prescribing information for PROVIGIL on adjacent page. For more information, visit www.PROVIGIL.com or call 1-800-896-5855.